"With our piggyBac DNA Modification System, we are able to consistently produce a CAR-T product that is 100% pure modified T cells and is predominantly comprised of T-stem cell memory (Tscm) cells, two key characteristics that enable more persistent and durable activity with less cytokine release," said Eric Ostertag, M.D., Ph.D., chief executive officer at Poseida. "PiggyBac combined with our suite of gene editing technologies lay the foundation for our pipeline of autologous and allogeneic cell therapies for liquid and solid tumor cancers, as well as gene therapies for orphan diseases."
Martin Giedlin , Ph.D., vice president, technical operations, led the presentation describing the enhanced cargo capacity and the clinical manufacturing method behind Poseida's non-viral piggyBac transposon. Highlights from the presentation:
About Poseida Therapeutics Inc.
Poseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida's lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene engineering technologies, including the piggyBac™ DNA Modification System, TAL-CLOVER™ and Cas-CLOVER™ site-specific nucleases, and Footprint-Free™ Gene Editing (FFGE). For more information, visit www.poseida.com .
Poseida has received grant funding from the California Institute for Regenerative Medicine to support the clinical development of P-BCMA-101.
Corporate Communications Contact: